Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of long-term bempedoic acid 180 mg
NL-OMON47830Phase 3Completed
- Sponsor
- Esperion Therapeutics
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bempedoic acid in hyperlipidemia, atherosclerotic disease and familial hypercholesterolemia (FH), sponsored by Esperion Therapeutics. Primary endpoint: Incidence of adverse events. Started Aug 2017; status: completed.
02
Drugs
bempedoic acid
03
Conditions
hyperlipidemiaatherosclerotic diseasefamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON47830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47830.